Pakistan to get ‘Made in India’ coronavirus vaccines soon
10 Mar 2021 Pakistan will be getting 45 million doses of Oxford-AstraZeneca s coronavirus vaccine. Gulf Today Report
Pakistan will soon get made-in-India coronavirus vaccines, sources have said, under the United Global Alliance for Vaccines and Immunisation or GAVI, a public-private global health partnership to increase access to immunisation in poor countries.
Pakistan will be getting 45 million doses of Oxford-AstraZeneca s coronavirus vaccine, being manufactured in India, according to reports in sections of the Indian media.
READ MORE
India has supplied vaccines to 65 countries so far under three categories – as part of the global vaccine alliance, in the form of grant or aid (free of cost), and through commercial sales. All of India s neighbours, except Pakistan, are among the countries that got these vaccines.
Why Indian pharma brands need a robust marketing strategy By Pragati - February 17, 2021
The pharma industry is booming. A few years ago, no one would have thought that the industry would grow to become one of the hottest topics on the internet, but after the year that was, pharma is all anyone’s talking about. And this means that all big pharma brand marketing strategies have had to adapt. Have a look at our Pharma Report - Racing for a vaccine: COVID-19 & the evolution of pharma.
The main focus is to ensure that the latest and most up-to-date information on the COVID vaccine is readily available, with another part of their marketing strategy to be limiting the spread of misinformation about the COVID vaccine, which has severely disrupted the adoption of vaccines all over the world. But for the purpose of this blog, I wanted to highlight the change in the pharmaceutical industry in India.
Court Rejects Move To Stop Covishield Trademark Use By Serum Institute Cutis Biotech filed a suit in the civil court seeking to restrain Adar Poonawalla s Serum Institute from using the trademark Covishield or other similar names for its COVID-19 vaccine
Updated: January 30, 2021 11:10 pm IST
Serum Institute s Covishield and Bharat Biotech s Covaxin were cleared for use in India
New Delhi:
Drug company Cutis Biotech s move to stop the Serum Institute of India from using the trademark Covishield has been rejected by a civil court in Pune, the Serum Institute s lawyers said in a note to the media.
Earlier this month, Cutis Biotech filed a suit in the civil court seeking to restrain Adar Poonawalla s Serum Institute from using the trademark Covishield or other similar names for its COVID-19 vaccine.